X
Search
X

Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.

X

Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

Biomarkers of apalutamide response identified in nonmetastatic CRPC

medwireNews: Further analysis of patients with nonmetastatic castration-resistant prostate cancer (CRPC) from the SPARTAN trial has identified molecular biomarkers associated with long-term responses to apalutamide.

Speaking to delegates at the 2021 Genitourinary Cancers Symposium, Felix Feng (University of California, San Francisco, USA) explained that the SPARTAN trial, reported previously by medwireNews, demonstrated a significant metastasis-free survival and overall survival benefit with the addition of apalutamide rather than placebo to androgen deprivation therapy (ADT).

Read the full article here.

source: Medwire News